A national survey of hereditary angioedema and acquired C1 inhibitor deficiency in the United Kingdom.
Yong, Patrick Fk Coulter, Tanya El-Shanwany, Tariq Garcez, Tomaz Hackett, Scott Jain, Rashmi Kiani-Alikhan, Sorena Manson, Ania Noorani, Sadia Stroud, Catherine
Yong, Patrick Fk
Coulter, Tanya
El-Shanwany, Tariq
Garcez, Tomaz
Hackett, Scott
Jain, Rashmi
Kiani-Alikhan, Sorena
Manson, Ania
Noorani, Sadia
Stroud, Catherine
Citations
Altmetric:
Affiliation
Frimley Health NHS Foundation Trust; Belfast Health and Social Care Trust; University Hospital of Wales; Sandwell and West Birmingham NHS Trust; et al.
Other Contributors
Publication date
2023-05-03
Subject
Collections
Research Projects
Organizational Units
Journal Issue
Abstract
Background: Detailed demographic data on people with hereditary angioedema and acquired C1 inhibitor deficiency in the UK are relatively limited. Better demographic data would be beneficial in planning service provision, identifying areas of improvement and improving care.
Objective: To obtain more accurate data on the demographics of hereditary angioedema and acquired C1 inhibitor deficiency in the UK, including treatment modalities and services available to patients.
Methods: A survey was distributed to all centres in the UK who look after patients with hereditary angioedema and acquired C1 inhibitor deficiency to collect these data.
Results: The survey identified 1152 patients with HAE-1/2 (58% female, 92% type 1), 22 patients with HAE with normal C1 inhibitor, and 91 patients with acquired C1 inhibitor deficiency. Data were provided by 37 centres across the UK. This gives a minimum prevalence of 1:59,000 for HAE-1/2, and 1: 734,000 for acquired C1 inhibitor deficiency in the UK. 45% of patients with HAE were on long-term prophylaxis with the most used medication being danazol (55% of all patients on LTP). 82% of patients with HAE had a home supply of acute treatment with C1 inhibitor or icatibant. 45% of patients had a supply of icatibant and 56% had a supply of C1 inhibitor at home.
Conclusions: Data obtained from the survey provides useful information about the demographics and treatment modalities used in HAE and acquired C1 inhibitor deficiency in the UK. These data are useful for planning service provision and improving services for these patients.
Citation
Yong PF, Coulter T, El-Shanwany T, Garcez T, Hackett S, Jain R, Kiani-Alikhan S, Manson A, Noorani S, Stroud C, Symons C, Sargur R, Steele C, Alachkar H, Anantharachagan A, Arkwright PD, Bernatoniene J, Bhole M, Brown L, Buckland M, Burns S, Chopra C, Darroch J, Drewe E, Edmonds J, Ekbote A, Elkhalifa S, Goddard S, Grosse-Kreul D, Gurugama P, Hague R, Herriot R, Herwadkar A, Hughes SM, Jones L, Lear S, McDermott E, Kham Murng SH, Price A, Redenbaugh V, Richter A, Riordan A, Shackley F, Stichbury J, Springett D, Tarzi MD, Thomas M, Vijayadurai P, Worth A. A national survey of hereditary angioedema and acquired C1 inhibitor deficiency in the United Kingdom. J Allergy Clin Immunol Pract
. 2023 Aug;11(8):2476-2483. doi: 10.1016/j.jaip.2023.04.035. Epub 2023 May 3.
Type
Article